Founder of EquityNet Research in 1999, Randy has more than 15 years equity and financial analysis experience. EquityNet was formed to provide the investing public with professional, independent, objective research on under-followed public companies, as well as industry and economic analysis. In 2008, Randy also founded The GSL Group, LLC, a company focused on private business valuation and related advisory services. He received his Bachelor’s Degree with honors in Finance from California State University, Fullerton, an MBA from the Anderson School of Management at UCLA and is a holder of the Chartered Financial Analyst (CFA) designation. He is also an assistant professor of business at LA Pierce College and American Jewish University. Randy is a member of the CFA Institute (CFAI) and the National Association of Certified Valuation Analysts (NACVA).
EquityNet Research Initiates Independent Research Coverage on American Jianye Greentech Holdings, Ltd.
LOS ANGELES, June 9, 2010 (GLOBE NEWSWIRE) — EquityNet Research, an independent West Coast equity research firm, announced today that it has initiated coverage of American Jianye Greentech Holdings, Ltd. (OTCBB: AJGH)
A full copy of the report and disclosure requirements are available at EquityNet Research’s Web site: www.equitynet.net.
American Jianye is a Heilongjiang-based developer and [...]
Health Insurers Taking Heat – Rightly So?
By Randy D. Lewis, CFA, MBA
Senior Analyst, EquityNet Research
February 22, 2010
I always tell myself I will not write on topics that are too “macroeconomic” or political, but that is what seems to be dominating the news lately – and I cannot help but mention the downward spiral of health insurance in the U.S.
All the [...]
EquityNet Research Initiates Independent Research Coverage on Biostar Pharmaceuticals, Inc.
LOS ANGELES – Feb. 18, 2010 — EquityNet Research, an independent West Coast equity research firm, announced today that it has initiated coverage of Biostar Pharmaceuticals, Inc. (OTCBB: BSPM).
A full copy of the report and disclosure requirements are available at EquityNet Research’s Web site: www.equitynet.net.
Biostar is a Xianyang-based developer, manufacturer and supplier of [...]
EquityNet Research Initiates Coverage on Huifeng Biopharmaceutical (OTCBB:HFGB)
LOS ANGELES – Feb. 10, 2010 — EquityNet Research, an independent West Coast equity research firm, announced today that it has initiated coverage on Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB: HFGB).
A full copy of the report and disclosure requirements are available at EquityNet Research’s Web site: www.equitynet.net.
Huifeng develops, produces and sells [...]
Research Report – SkyPeople Fruit Juice Inc.
“EquityNet Research, a West-Coast independent equity research firm, announced today that it has initiated coverage on the SkyPeople Fruit Juice, Inc. (AMEX:SPU) with a ‘Buy’ recommendation and a 12-month price target of $13.29 per share. SkyPeople, through its subsidiary Shaanxi Tianren Organic Food Co., Ltd., engages in the production and sale of special concentrated [...]
2010 Outlook – Does Optimism = Recovery?
By Randy D. Lewis, CFA, MBA
Senior Analyst, EquityNet Research
January 11, 2010
As we start a new year, not to mention decade, thoughts and discussions turn to what lies ahead for our economy and the financial markets. Many investors and the professionals that serve them – money mangers, brokers and investor relations consultants – take a [...]
Financial Oversight – What is too Little and too Much?
By Randy D. Lewis, CFA, MBA
Senior Analyst, EquityNet Research
December 21, 2009
“Sweeping overhaul” was the term used to describe a new financial oversight bill that narrowly passed the House (223-202) last week, and many players in the industry, from investment managers, brokerage houses, to even investor relations professionals, are chiming in with their thoughts – and [...]
